Search hospitals > Rhode Island > Providence
The Miriam Hospital
Claim this profileProvidence, Rhode Island 02906
Global Leader in HIV Infection
Global Leader in Human Immunodeficiency Virus Infection
Conducts research for Lung Cancer
Conducts research for Obesity
Conducts research for Peripheral Artery Disease
367 reported clinical trials
14 medical researchers
Summary
The Miriam Hospital is a medical facility located in Providence, Rhode Island. This center is recognized for care of HIV Infection, Human Immunodeficiency Virus Infection, Lung Cancer, Obesity, Peripheral Artery Disease and other specialties. The Miriam Hospital is involved with conducting 367 clinical trials across 382 conditions. There are 14 research doctors associated with this hospital, such as Peter Soukas, MD, Don Dizon, MD, Eleftherios Mylonakis, MD, and Rimini Breakstone.Top PIs
Peter Soukas, MDThe Miriam Hospital5 years of reported clinical research
Studies Peripheral Artery Disease
Studies Peripheral Arterial Disease
9 reported clinical trials
11 drugs studied
Don Dizon, MDRhode Island Hospital7 years of reported clinical research
Studies Endometrial Cancer
Studies Breast Cancer
6 reported clinical trials
22 drugs studied
Eleftherios Mylonakis, MDHouston Methodist Hospital1 year of reported clinical research
Studies Post-COVID Syndrome
Studies COVID-19
5 reported clinical trials
10 drugs studied
Rimini BreakstoneRhode Island Hospital3 years of reported clinical research
Studies Colorectal Cancer
Studies Colon Cancer
5 reported clinical trials
15 drugs studied
Clinical Trials running at The Miriam Hospital
Lung Cancer
Obesity
Peripheral Artery Disease
Breast cancer
Peripheral Arterial Disease
Critical Limb Ischemia
Multiple Myeloma
Breast Cancer
ALK Gene Rearrangement
Peripheral artery disease
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
PF-07934040 + Other Anti-Cancer Therapies
for Non-Small Cell Lung Cancer
The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose. This study is seeking participants who have solid tumors (a mass of abnormal cells that forms a lump or growth in the body) that: * are advanced (cancer that doesn't disappear or stay away with treatment) and * have a KRAS gene mutation (a change in the DNA of the KRAS gene that can cause cells to grow in very high numbers). This includes (but limited to) the following cancer types: Non-Small Cell Lung Cancer (NSCLC): It's a type of lung cancer where the cells grow slowly but often spread to other parts of the body. Colorectal Cancer (CRC): This is a disease where cells in the colon (a part of large intestine) or rectum grow out of control. Pancreatic ductal adenocarcinoma (PDAC): This is a cancer that starts in the ducts of the pancreas but can spread quickly to other parts of the body. Pancreas is a long, flat gland that lies in the abdomen behind the stomach. Pancreas creates enzymes that help with digestion. It also makes hormones that can help control your blood sugar levels. All participants in this study will take the study medication (PF-07934040) as pill by mouth twice a day repeating for 21-day or 28-day cycles. Depending on which part of the study participants are enrolled into they will receive the study medication (PF-07934040 alone or in combination with other anti-cancer medications). These anti-cancer medications will be given in the study clinic by intravenous (IV) that is directly injected into the veins at various times (depending on the treatment) during the 21-day or 28-day cycle. Participants can continue to take the study medication (PF-07934040) and the combination anti-cancer therapy until their cancer is no longer responding. The study will look at the experiences of people receiving the study medicines. This will help see if the study medicines are safe and effective. Participants will be involved in this study for up to 4 years. During this time, they will come into the clinic between 1 to 4 times in each 21-day or 28-day cycle. After they have stopped taking the study medication (at about at 2 years) they will be followed for another two years to see how they are doing.
Recruiting1 award Phase 15 criteria
DF6002 + Nivolumab
for Advanced Cancer
This trial is testing a new drug, DF6002, alone and with an existing drug, Nivolumab, in patients with advanced solid tumors. These patients have cancers that are hard to treat with standard methods. DF6002 might help shrink or slow down tumors, while Nivolumab boosts the immune system to fight cancer.
Recruiting1 award Phase 15 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at The Miriam Hospital?
The Miriam Hospital is a medical facility located in Providence, Rhode Island. This center is recognized for care of HIV Infection, Human Immunodeficiency Virus Infection, Lung Cancer, Obesity, Peripheral Artery Disease and other specialties. The Miriam Hospital is involved with conducting 367 clinical trials across 382 conditions. There are 14 research doctors associated with this hospital, such as Peter Soukas, MD, Don Dizon, MD, Eleftherios Mylonakis, MD, and Rimini Breakstone.
Where is The Miriam Hospital located?
**The Miriam Hospital**
- **Address:** 164 Summit Ave, Providence, RI 02906
- **Directions:** From points south, take I-95 North to Exit 25 (North Main Street). Proceed to take the first sub-exit before the bus stop.
Who should I call to ask about financial aid or insurance network?
**The Miriam Hospital Financial and Insurance Assistance**
- **Financial Assistance Department:** For patients meeting specific income guidelines, assistance is available. Contact at 401-793-2206.
- **Insurance and Billing Department:** Assistance with understanding insurance policies and bills. Contact at 401-444-6966.
What insurance does The Miriam Hospital accept?
The Miriam Hospital accepts a wide range of insurance plans, including but not limited to Aetna, Blue Cross Blue Shield of Rhode Island, HealthMate Coast-to-Coast, and United HealthCare. Medicare coverage includes Medicare Part B and Medicare Advantage Plans from several providers. Patients are advised to confirm their insurance coverage and plan acceptance with The Miriam Hospital directly.
What awards or recognition has The Miriam Hospital received?
The Miriam Hospital in Providence, Rhode Island, has been awarded an $11.1 million grant by the National Institutes of Health. This funding will support the establishment of a Center of Biomedical Research Excellence (COBRE) dedicated to studying stress, trauma, and resilience. The grant will enhance the hospital's research capabilities and foster collaborations with regional healthcare institutions to advance knowledge on the impact of stress and trauma on health and wellbeing.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.